Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ru...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2017-08, Vol.130 (9), p.1125-1131
Main Authors: Newberry, Kate J., Patel, Keyur, Masarova, Lucia, Luthra, Rajyalakshmi, Manshouri, Taghi, Jabbour, Elias, Bose, Prithviraj, Daver, Naval, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Clonal Evolution
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Myeloid Neoplasia
Primary Myelofibrosis - drug therapy
Primary Myelofibrosis - genetics
Primary Myelofibrosis - pathology
Pyrazoles - therapeutic use
Treatment Outcome
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c529t-37569d74ed0a647922d9b85b2bc6f15633486c5bc74395745f5432d5603756623
cites cdi_FETCH-LOGICAL-c529t-37569d74ed0a647922d9b85b2bc6f15633486c5bc74395745f5432d5603756623
container_end_page 1131
container_issue 9
container_start_page 1125
container_title Blood
container_volume 130
creator Newberry, Kate J.
Patel, Keyur
Masarova, Lucia
Luthra, Rajyalakshmi
Manshouri, Taghi
Jabbour, Elias
Bose, Prithviraj
Daver, Naval
Cortes, Jorge
Kantarjian, Hagop
Verstovsek, Srdan
description Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ruxolitinib. Here we describe outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study at our center. After a median follow-up of 79 months, 86 patients had discontinued ruxolitinib (30 of whom died while on therapy). The median follow-up after ruxolitinib discontinuation for the remaining 56 patients was 32 months, with median survival after discontinuation of 14 months. Platelets
doi_str_mv 10.1182/blood-2017-05-783225
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5580275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120329141</els_id><sourcerecordid>1915881089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-37569d74ed0a647922d9b85b2bc6f15633486c5bc74395745f5432d5603756623</originalsourceid><addsrcrecordid>eNp9UcFu1TAQtBCIvrb8AUI5ckm7dry2c0FCTy1UqgQHOFuO7YCRYxc7eWr_vnl9pZQLp11pd2ZnZwh5S-GMUsXOh5izaxlQ2QK2UnWM4QuyochUC8DgJdkAgGh5L-kROa71FwDlHcPX5IgpITkwsSFftzEnExu_y3GZQ06NSa7Jy2zz5GsTUjPd-ZjHMJRcQ23MOPvSlOU2xzCHFIbGhWpzWvvF7PGn5NVoYvVvHusJ-X558W37ub3-8ulq-_G6tcj6ue0kit5J7h0YwWXPmOsHhQMbrBgpiq7jSlgcrORdj5LjiKt2hwL2SMG6E_LhwHuzDJN31qe5mKhvSphMudPZBP3vJIWf-kfeaUQFTOJK8P6RoOTfi6-zntZPfIwm-bxUTXuKSlFQ_brKD6t2NaEWPz6doaD3YeiHMPQ-DA2oD2GssHfPJT6B_rj_9we_GrULvuhqg0_Wu1C8nbXL4f8X7gH0g5zZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1915881089</pqid></control><display><type>article</type><title>Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation</title><source>ScienceDirect Journals</source><creator>Newberry, Kate J. ; Patel, Keyur ; Masarova, Lucia ; Luthra, Rajyalakshmi ; Manshouri, Taghi ; Jabbour, Elias ; Bose, Prithviraj ; Daver, Naval ; Cortes, Jorge ; Kantarjian, Hagop ; Verstovsek, Srdan</creator><creatorcontrib>Newberry, Kate J. ; Patel, Keyur ; Masarova, Lucia ; Luthra, Rajyalakshmi ; Manshouri, Taghi ; Jabbour, Elias ; Bose, Prithviraj ; Daver, Naval ; Cortes, Jorge ; Kantarjian, Hagop ; Verstovsek, Srdan</creatorcontrib><description>Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ruxolitinib. Here we describe outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study at our center. After a median follow-up of 79 months, 86 patients had discontinued ruxolitinib (30 of whom died while on therapy). The median follow-up after ruxolitinib discontinuation for the remaining 56 patients was 32 months, with median survival after discontinuation of 14 months. Platelets &lt;260 × 109/L at the start of therapy or &lt;100 × 109/L at the time of discontinuation were associated with shorter survival after discontinuation. Of 62 patients with molecular data at baseline and follow-up, 22 (35%) acquired a new mutation while receiving ruxolitinib (14 [61%] in ASXL1). Patients showing clonal evolution had significantly shorter survival after discontinuation (6 vs 16 months). Transfusion dependency was the only clinical variable associated with clonal evolution. These findings underscore the need for novel therapies and suggest that clonal evolution or decreasing platelet counts while on ruxolitinib therapy may be markers of poor prognosis. •Survival of patients with MF after ruxolitinib discontinuation is poor, with median survival of 14 months.•Low platelets at the start or end of therapy or clonal evolution while on therapy are associated with an even worse prognosis.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2017-05-783225</identifier><identifier>PMID: 28674026</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Clonal Evolution ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Myeloid Neoplasia ; Primary Myelofibrosis - drug therapy ; Primary Myelofibrosis - genetics ; Primary Myelofibrosis - pathology ; Pyrazoles - therapeutic use ; Treatment Outcome ; Withholding Treatment</subject><ispartof>Blood, 2017-08, Vol.130 (9), p.1125-1131</ispartof><rights>2017 American Society of Hematology</rights><rights>2017 by The American Society of Hematology.</rights><rights>2017 by The American Society of Hematology 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-37569d74ed0a647922d9b85b2bc6f15633486c5bc74395745f5432d5603756623</citedby><cites>FETCH-LOGICAL-c529t-37569d74ed0a647922d9b85b2bc6f15633486c5bc74395745f5432d5603756623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120329141$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28674026$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Newberry, Kate J.</creatorcontrib><creatorcontrib>Patel, Keyur</creatorcontrib><creatorcontrib>Masarova, Lucia</creatorcontrib><creatorcontrib>Luthra, Rajyalakshmi</creatorcontrib><creatorcontrib>Manshouri, Taghi</creatorcontrib><creatorcontrib>Jabbour, Elias</creatorcontrib><creatorcontrib>Bose, Prithviraj</creatorcontrib><creatorcontrib>Daver, Naval</creatorcontrib><creatorcontrib>Cortes, Jorge</creatorcontrib><creatorcontrib>Kantarjian, Hagop</creatorcontrib><creatorcontrib>Verstovsek, Srdan</creatorcontrib><title>Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation</title><title>Blood</title><addtitle>Blood</addtitle><description>Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ruxolitinib. Here we describe outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study at our center. After a median follow-up of 79 months, 86 patients had discontinued ruxolitinib (30 of whom died while on therapy). The median follow-up after ruxolitinib discontinuation for the remaining 56 patients was 32 months, with median survival after discontinuation of 14 months. Platelets &lt;260 × 109/L at the start of therapy or &lt;100 × 109/L at the time of discontinuation were associated with shorter survival after discontinuation. Of 62 patients with molecular data at baseline and follow-up, 22 (35%) acquired a new mutation while receiving ruxolitinib (14 [61%] in ASXL1). Patients showing clonal evolution had significantly shorter survival after discontinuation (6 vs 16 months). Transfusion dependency was the only clinical variable associated with clonal evolution. These findings underscore the need for novel therapies and suggest that clonal evolution or decreasing platelet counts while on ruxolitinib therapy may be markers of poor prognosis. •Survival of patients with MF after ruxolitinib discontinuation is poor, with median survival of 14 months.•Low platelets at the start or end of therapy or clonal evolution while on therapy are associated with an even worse prognosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Clonal Evolution</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myeloid Neoplasia</subject><subject>Primary Myelofibrosis - drug therapy</subject><subject>Primary Myelofibrosis - genetics</subject><subject>Primary Myelofibrosis - pathology</subject><subject>Pyrazoles - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Withholding Treatment</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9UcFu1TAQtBCIvrb8AUI5ckm7dry2c0FCTy1UqgQHOFuO7YCRYxc7eWr_vnl9pZQLp11pd2ZnZwh5S-GMUsXOh5izaxlQ2QK2UnWM4QuyochUC8DgJdkAgGh5L-kROa71FwDlHcPX5IgpITkwsSFftzEnExu_y3GZQ06NSa7Jy2zz5GsTUjPd-ZjHMJRcQ23MOPvSlOU2xzCHFIbGhWpzWvvF7PGn5NVoYvVvHusJ-X558W37ub3-8ulq-_G6tcj6ue0kit5J7h0YwWXPmOsHhQMbrBgpiq7jSlgcrORdj5LjiKt2hwL2SMG6E_LhwHuzDJN31qe5mKhvSphMudPZBP3vJIWf-kfeaUQFTOJK8P6RoOTfi6-zntZPfIwm-bxUTXuKSlFQ_brKD6t2NaEWPz6doaD3YeiHMPQ-DA2oD2GssHfPJT6B_rj_9we_GrULvuhqg0_Wu1C8nbXL4f8X7gH0g5zZ</recordid><startdate>20170831</startdate><enddate>20170831</enddate><creator>Newberry, Kate J.</creator><creator>Patel, Keyur</creator><creator>Masarova, Lucia</creator><creator>Luthra, Rajyalakshmi</creator><creator>Manshouri, Taghi</creator><creator>Jabbour, Elias</creator><creator>Bose, Prithviraj</creator><creator>Daver, Naval</creator><creator>Cortes, Jorge</creator><creator>Kantarjian, Hagop</creator><creator>Verstovsek, Srdan</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170831</creationdate><title>Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation</title><author>Newberry, Kate J. ; Patel, Keyur ; Masarova, Lucia ; Luthra, Rajyalakshmi ; Manshouri, Taghi ; Jabbour, Elias ; Bose, Prithviraj ; Daver, Naval ; Cortes, Jorge ; Kantarjian, Hagop ; Verstovsek, Srdan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-37569d74ed0a647922d9b85b2bc6f15633486c5bc74395745f5432d5603756623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Clonal Evolution</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myeloid Neoplasia</topic><topic>Primary Myelofibrosis - drug therapy</topic><topic>Primary Myelofibrosis - genetics</topic><topic>Primary Myelofibrosis - pathology</topic><topic>Pyrazoles - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Withholding Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Newberry, Kate J.</creatorcontrib><creatorcontrib>Patel, Keyur</creatorcontrib><creatorcontrib>Masarova, Lucia</creatorcontrib><creatorcontrib>Luthra, Rajyalakshmi</creatorcontrib><creatorcontrib>Manshouri, Taghi</creatorcontrib><creatorcontrib>Jabbour, Elias</creatorcontrib><creatorcontrib>Bose, Prithviraj</creatorcontrib><creatorcontrib>Daver, Naval</creatorcontrib><creatorcontrib>Cortes, Jorge</creatorcontrib><creatorcontrib>Kantarjian, Hagop</creatorcontrib><creatorcontrib>Verstovsek, Srdan</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Newberry, Kate J.</au><au>Patel, Keyur</au><au>Masarova, Lucia</au><au>Luthra, Rajyalakshmi</au><au>Manshouri, Taghi</au><au>Jabbour, Elias</au><au>Bose, Prithviraj</au><au>Daver, Naval</au><au>Cortes, Jorge</au><au>Kantarjian, Hagop</au><au>Verstovsek, Srdan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2017-08-31</date><risdate>2017</risdate><volume>130</volume><issue>9</issue><spage>1125</spage><epage>1131</epage><pages>1125-1131</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ruxolitinib. Here we describe outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study at our center. After a median follow-up of 79 months, 86 patients had discontinued ruxolitinib (30 of whom died while on therapy). The median follow-up after ruxolitinib discontinuation for the remaining 56 patients was 32 months, with median survival after discontinuation of 14 months. Platelets &lt;260 × 109/L at the start of therapy or &lt;100 × 109/L at the time of discontinuation were associated with shorter survival after discontinuation. Of 62 patients with molecular data at baseline and follow-up, 22 (35%) acquired a new mutation while receiving ruxolitinib (14 [61%] in ASXL1). Patients showing clonal evolution had significantly shorter survival after discontinuation (6 vs 16 months). Transfusion dependency was the only clinical variable associated with clonal evolution. These findings underscore the need for novel therapies and suggest that clonal evolution or decreasing platelet counts while on ruxolitinib therapy may be markers of poor prognosis. •Survival of patients with MF after ruxolitinib discontinuation is poor, with median survival of 14 months.•Low platelets at the start or end of therapy or clonal evolution while on therapy are associated with an even worse prognosis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28674026</pmid><doi>10.1182/blood-2017-05-783225</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2017-08, Vol.130 (9), p.1125-1131
issn 0006-4971
1528-0020
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5580275
source ScienceDirect Journals
subjects Adult
Aged
Aged, 80 and over
Clonal Evolution
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Myeloid Neoplasia
Primary Myelofibrosis - drug therapy
Primary Myelofibrosis - genetics
Primary Myelofibrosis - pathology
Pyrazoles - therapeutic use
Treatment Outcome
Withholding Treatment
title Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A46%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clonal%20evolution%20and%20outcomes%20in%20myelofibrosis%20after%20ruxolitinib%20discontinuation&rft.jtitle=Blood&rft.au=Newberry,%20Kate%20J.&rft.date=2017-08-31&rft.volume=130&rft.issue=9&rft.spage=1125&rft.epage=1131&rft.pages=1125-1131&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2017-05-783225&rft_dat=%3Cproquest_pubme%3E1915881089%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c529t-37569d74ed0a647922d9b85b2bc6f15633486c5bc74395745f5432d5603756623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1915881089&rft_id=info:pmid/28674026&rfr_iscdi=true